Mylan pays $465 million to settle EpiPen Medicaid rebate dispute

(Reuters) - Mylan NV on Friday said it will pay $465 million to settle the question of whether misclassification of its EpiPen emergency allergy treatment resulted in underpayment of rebates to the U.S. Medicaid healthcare program.